Reduced financial support |
Limited budgets |
Less discovery of novel
molecules |
Reduced clinical research workforce
|
Contract COVID-19
Reduced staff (furloughs, job loss)
Work from home mandates
|
Delay in recruitment
Delays in data collection and submission
Potential compromise in data quality
|
Reduced laboratory workforce
|
Contract COVID-19
Reduced staff (furloughs, job loss)
Work from home mandates
Exclusion of trainees due to social distancing
|
Little to no laboratory research being performed beyond “essential”
Delays in publications, report deadlines due to incomplete data
Delayed or compromised training of future workforce
|
Reallocation of resources |
Shifting portfolios to COVID-19 |
Less
discovery, less clinical trials in oncology |
Implementation of novel therapeutics
|
Deferring trials involving agents that suppress immune system, increase
susceptibly to COVID-19
Minimizing therapy-related risk to the patient
|
Less discovery, less clinical trials in oncology, less enrollment of
eligible patients
|